Catherine M. Szyman Sells 10,000 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) VP Catherine M. Szyman sold 10,000 shares of the business’s stock in a transaction on Friday, January 14th. The shares were sold at an average price of $119.53, for a total transaction of $1,195,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

EW stock traded down $2.20 during trading on Friday, hitting $118.26. The company had a trading volume of 2,112,636 shares, compared to its average volume of 2,161,996. The firm has a market capitalization of $73.83 billion, a price-to-earnings ratio of 51.26, a P/E/G ratio of 3.45 and a beta of 1.10. The business has a 50 day moving average of $119.68 and a 200 day moving average of $115.70. Edwards Lifesciences Co. has a fifty-two week low of $78.44 and a fifty-two week high of $131.73. The company has a current ratio of 3.64, a quick ratio of 2.87 and a debt-to-equity ratio of 0.11.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, October 27th. The medical research company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.01. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. Edwards Lifesciences had a net margin of 29.00% and a return on equity of 28.13%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.51 earnings per share. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.26 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Edwards Lifesciences by 0.3% in the 3rd quarter. BlackRock Inc. now owns 53,033,851 shares of the medical research company’s stock valued at $6,003,965,000 after acquiring an additional 172,681 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Edwards Lifesciences by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 23,357,315 shares of the medical research company’s stock valued at $2,419,116,000 after acquiring an additional 186,344 shares during the last quarter. Capital International Investors lifted its holdings in Edwards Lifesciences by 5.9% in the 2nd quarter. Capital International Investors now owns 20,002,880 shares of the medical research company’s stock valued at $2,071,700,000 after acquiring an additional 1,115,719 shares during the last quarter. Sands Capital Management LLC lifted its holdings in Edwards Lifesciences by 0.8% in the 3rd quarter. Sands Capital Management LLC now owns 13,550,416 shares of the medical research company’s stock valued at $1,534,043,000 after acquiring an additional 113,882 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Edwards Lifesciences by 3.5% in the 3rd quarter. Geode Capital Management LLC now owns 10,582,581 shares of the medical research company’s stock valued at $1,194,730,000 after acquiring an additional 358,020 shares during the last quarter. 80.79% of the stock is owned by institutional investors and hedge funds.

Several research firms have weighed in on EW. Royal Bank of Canada began coverage on shares of Edwards Lifesciences in a research note on Thursday, December 9th. They set an “outperform” rating and a $142.00 target price for the company. Citigroup upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the company from $120.00 to $142.00 in a research note on Wednesday, December 15th. SVB Leerink boosted their target price on shares of Edwards Lifesciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Thursday, December 9th. Jefferies Financial Group boosted their target price on shares of Edwards Lifesciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, October 29th. Finally, Piper Sandler boosted their target price on shares of Edwards Lifesciences from $123.00 to $133.00 and gave the company an “overweight” rating in a research note on Wednesday, December 8th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $125.30.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.

Recommended Story: What are retained earnings?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.